Loading…
← CockpitCompetitor Analysis › MTRI Mentari Therapeutics, Inc.Open in the cockpit ↗

Mentari Therapeutics, Inc.MTRICompetitor analysis, valuation and peers

United States · USD·Industrials›Miscellaneous Commercial Services
Momentum laggard 0
Mkt cap
$807M
US dollars, full cap
$/day
$726,996
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 9.8%
Hurdle
n/a
no reverse DCF
Next earnings
90 days
16 Feb 2027
Close · USD$15.29
1D-12.7%
1W-2.1%
1M-88.6%
3M-90.3%
6M-90.5%
YTD-85.6%
1Y-90.7%
ATR %83.5%
Beta2.67
52w lowhigh93.4% off high

What Mentari Therapeutics does

Employees: 6

Mentari Therapeutics at a glance

Size Mentari Therapeutics (MTRI) is a United States Industrials company (Miscellaneous Commercial Services) with a market value of $807M, the 2362nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $15.29 on 18 Nov 2026.

Performance Over six months the shares fell 90.5%, against -8.4% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue fell 82.9% over the last twelve months (peer median +6.4%); the operating margin is -1,238.6% (peer median 9.7%).

Valuation It trades at 982.9× enterprise value to sales against a peer median of 4.1× (most expensive of 20).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

05010021 May 202621 Aug 202618 Nov 2026Peer median 92MTRI 9
Six months, rebased to 100: Mentari Therapeutics against the median of its 20 peers (local-currency closes).

Mentari Therapeutics financials

Reported figures in USD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue$820,188$0$0$4.60M$4.14M
Revenue growth——-100%+11%—
Gross profit-$589,717-$708,356-$532,328$496,395$1.14M
EBITDA-$9.39M-$9.19M-$7.91M-$7.53M-$7.81M
Net income-$13.2M-$12.6M-$8.16M-$7.68M-$7.95M
Free cash flow-$8.16M-$8.64M-$8.10M-$7.00M-$7.44M
Capital expenditure$0$0$0$9,293$160,014
Total debt$0$0$741,262$962,662$391,707

Quarterly statements and history in the cockpit →

Mentari Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-50%0%BV6887879715KARTASK6033730009K0002649603955IPO688334IBEX9716300860001207CCL301608MTRI6-month return →1-month return →
Up and to the right = strong over both horizons. Mentari Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%0×500×1,000×BV68878797150009K0603955688530IPO300860MTRIRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Mentari Therapeutics is the large dot.

Mentari Therapeutics competitors and peer comparison

How Mentari Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mentari Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureMTRIPeer medianRank in peer set
1-month return-88.6%-5.3%lowest of 21
6-month return-90.5%-8.4%lowest of 21
Distance from 52-week high-93.4%-31.3%lowest of 21
Revenue growth (TTM)-82.9%+6.4%lowest of 21
Operating margin-1,238.6%9.7%lowest of 21
EV / Sales982.9×4.1×most expensive of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Mentari Therapeutics MTRIUnited States$807M-91%-83%-1,239%982.9×n/an/a
BrightView BVUnited States$803M-29%+1%4%0.9×n/an/a
Beijing Haitian Ruisheng Science Technology 688787.SSChina$801M-37%+34%4%11.9×n/an/a
transcosmos 9715.TJapan$814M-11%+6%4%0.2×-18.2%+3.2%
Karnov KAR.STSweden$820M+9%-4%20%4.1×5.1%+27.9%
TaskUs TASKUnited States$827M+50%+9%12%0.9×1.3%+19.9%
Anbang Save-Guard 603373.SSChina$779M+6%-1%14%1.9×5.6%+5.6%
Aimed Bio 0009K0.KSSouth Korea$778M-61%+228%34%13.8×10.2%+652.2%
Beyondsoft 002649.SZChina$769M-14%-6%2%0.6×7.0%+9.2%
Daqian Ecology & Environment 603955.SSChina$769M+21%+217%-53%14.7×n/an/a
Shaanxi Fenghuo Electronics 000561.SZChina$851M-27%+8%-26%4.1×n/an/a
Omat Advanced Materials (Guangdong) 688530.SSChina$757M-19%+82%9%5.7×n/an/a
IP Group plc IPO.LUnited Kingdom$865M+11%-37%51%15.5×n/an/a
Xi'an High Voltage Apparatus Research Institute 688334.SSChina$866M-11%+4%29%4.5×-2.9%+20.3%
AXISCADES Technologies AXISCADES.NSIndia$871M-6%+5%10%7.4×n/an/a
IBEX IBEXUnited States$744M+79%+15%9%1.1×1.0%+7.7%
NOMURA 9716.TJapan$880M+7%-10%7%0.6×-7.5%+8.6%
Funshine Culture 300860.SZChina$739M0%-49%-35%10.1×21.5%-24.6%
Shandong Link Science and Technology 001207.SZChina$733M-24%+7%13%1.7×-5.5%+18.9%
Cuscal CCL.AXAustralia$728M+17%+19%12%n/an/an/a
Shenzhen Boshijie Technology 301608.SZChina$896M-31%+15%14%2.5×n/an/a

Questions

Which companies are Mentari Therapeutics's closest peers?
The cockpit's peer set: BrightView (BV), Beijing Haitian Ruisheng Science Technology (688787.SS), transcosmos (9715.T), Karnov (KAR.ST), TaskUs (TASK), Anbang Save-Guard (603373.SS), Aimed Bio (0009K0.KS), Beyondsoft (002649.SZ).
Is Mentari Therapeutics expensive compared with its peers?
On ev / sales it trades at 982.9× against a peer median of 4.1×, most expensive of 20 in its peer set.
How has Mentari Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -90.5% against -8.4% for the median peer; over one year -90.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.